Abundance of Synaptic Vesicle-Related Proteins in Alpha-Synuclein-Containing Protein Inclusions Suggests a Targeted Formation Mechanism.


Journal

Neurotoxicity research
ISSN: 1476-3524
Titre abrégé: Neurotox Res
Pays: United States
ID NLM: 100929017

Informations de publication

Date de publication:
May 2019
Historique:
received: 15 06 2018
accepted: 08 02 2019
revised: 31 01 2019
pubmed: 24 2 2019
medline: 24 5 2019
entrez: 24 2 2019
Statut: ppublish

Résumé

Proteinaceous α-synuclein-containing inclusions are found in affected brain regions in patients with Parkinson's disease (PD), Dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). These appear in neurons as Lewy bodies in both PD and DLB and as glial cytoplasmic inclusions (GCIs) in oligodendrocytes in MSA. The role they play in the pathology of the diseases is unknown, and relatively little is still known about their composition. By purifying the inclusions from the surrounding tissue and comprehensively analysing their protein composition, vital clues to the formation mechanism and role in the disease process may be found. In this study, Lewy bodies were purified from postmortem brain tissue from DLB cases (n = 2) and GCIs were purified from MSA cases (n = 5) using a recently improved purification method, and the purified inclusions were analysed by mass spectrometry. Twenty-one percent of the proteins found consistently in the GCIs and LBs were synaptic-vesicle related. Identified proteins included those associated with exosomes (CD9), clathrin-mediated endocytosis (clathrin, AP-2 complex, dynamin), retrograde transport (dynein, dynactin, spectrin) and synaptic vesicle fusion (synaptosomal-associated protein 25, vesicle-associated membrane protein 2, syntaxin-1). This suggests that the misfolded or excess α-synuclein may be targeted to inclusions via vesicle-mediated transport, which also explains the presence of the neuronal protein α-synuclein within GCIs.

Identifiants

pubmed: 30796693
doi: 10.1007/s12640-019-00014-0
pii: 10.1007/s12640-019-00014-0
doi:

Substances chimiques

alpha-Synuclein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

883-897

Références

J Neurochem. 1999 Nov;73(5):2093-100
pubmed: 10537069
J Biol Chem. 2000 Jul 14;275(28):21500-7
pubmed: 10764738
Neurosci Lett. 2000 Jun 16;287(1):65-7
pubmed: 10841992
J Neurosci Res. 2000 Oct 1;62(1):9-14
pubmed: 11002283
Neurol Sci. 2001 Feb;22(1):97-9
pubmed: 11487219
Neuroreport. 2002 Jul 19;13(10):1305-8
pubmed: 12151792
Ann N Y Acad Sci. 2003 Jun;991:1-14
pubmed: 12846969
Lancet Neurol. 2004 Jan;3(1):19-28
pubmed: 14693108
J Clin Neurosci. 2004 Feb;11(2):119-23
pubmed: 14732367
J Biol Chem. 2005 Feb 18;280(7):5703-15
pubmed: 15590652
Brain Res Mol Brain Res. 2005 Mar 24;134(1):57-66
pubmed: 15790530
J Neural Transm (Vienna). 2005 Dec;112(12):1605-12
pubmed: 16284906
J Neural Transm (Vienna). 2005 Dec;112(12):1613-24
pubmed: 16284907
Proteomics. 2006 Apr;6(8):2334-7
pubmed: 16493709
Nat Genet. 2006 May;38(5):518-20
pubmed: 16604072
Nat Genet. 2006 May;38(5):515-7
pubmed: 16604074
Acta Neuropathol. 2006 Nov;112(5):531-8
pubmed: 16855831
Neuropathology. 2006 Aug;26(4):338-45
pubmed: 16961071
Trends Mol Med. 2006 Nov;12(11):521-8
pubmed: 17027339
J Neurochem. 2007 Jun;101(6):1448-62
pubmed: 17355250
Brain Pathol. 2007 Apr;17(2):139-45
pubmed: 17388944
Neurology. 2007 Nov 27;69(22):2093-104
pubmed: 17761553
Clin Genet. 2007 Nov;72(5):387-93
pubmed: 17868389
Neurochem Res. 2008 Mar;33(3):589-97
pubmed: 17940895
J Neurochem. 2008 Jan;104(2):298-305
pubmed: 17961149
Neuropathology. 2007 Oct;27(5):484-93
pubmed: 18018485
Neuropathology. 2007 Oct;27(5):494-506
pubmed: 18018486
J Neurol. 2008 Sep;255 Suppl 5:18-32
pubmed: 18787879
Ann Neurol. 2008 Sep;64(3):239-46
pubmed: 18825660
Curr Protein Pept Sci. 2009 Oct;10(5):483-99
pubmed: 19538146
J Proteomics. 2009 Nov 2;73(1):10-29
pubmed: 19632367
Hum Mol Genet. 2009 Oct 15;18(R2):R169-76
pubmed: 19808793
Proteomics. 2011 Nov;11(22):4385-96
pubmed: 21905220
Oxid Med Cell Longev. 2014;2014:520316
pubmed: 25009690
J Neurosci Methods. 2016 Jun 15;266:141-50
pubmed: 27039974
Brain Res. 1993 Feb 12;603(1):121-4
pubmed: 7680936
Am J Pathol. 1996 May;148(5):1517-29
pubmed: 8623921
Mov Disord. 1997 Mar;12(2):133-47
pubmed: 9087971
Acta Neuropathol. 1997 Jun;93(6):585-91
pubmed: 9194897
Acta Neuropathol. 1998 Aug;96(2):111-5
pubmed: 9705124

Auteurs

Amellia McCormack (A)

Flinders Proteomics Facility, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042, Australia.

Damien J Keating (DJ)

College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042, Australia.

Nusha Chegeni (N)

Flinders Proteomics Facility, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042, Australia.

Alex Colella (A)

Flinders Proteomics Facility, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042, Australia.
Department of Immunology, Flinders Medical Centre and Flinders University, SA Pathology, Bedford Park, South Australia, 5042, Australia.

Jing Jing Wang (JJ)

Department of Immunology, Flinders Medical Centre and Flinders University, SA Pathology, Bedford Park, South Australia, 5042, Australia.

Tim Chataway (T)

Flinders Proteomics Facility, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042, Australia. tim.chataway@flinders.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH